WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5
WntResearch today announces that the safety evaluation from the first cohort in the dose-finding part of the proof-of-concept study NeoFox, support continued evaluation of the drug candidate Foxy-5 at an additional higher dose. After the most appropriate dose has been defined in the spring, approximately 80 patients with colon cancer will be treated. An initial efficacy analysis is planned based on data from 20 patients in active treatment and 20 patients in the control group."We are pleased that patient recruitment to the first dose group in the NeoFox study has been completed so quickly